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AbsTrACT
Introduction Males have a higher prevalence 
of asthma in childhood, whereas females have a 
higher prevalence in adolescence and adulthood. the 
’adolescent switch’ observed between sexes during 
puberty has been hypothesised to be due to fluctuating 
sex hormones. robust evidence of the involvement of 
sex hormones in asthma could lead to development of 
therapeutic interventions.
Methods We combine observational evidence using 
longitudinal data on sex hormone-binding globulin 
(SHBg), total and bioavailable testosterone and asthma 
from a subset of males (n=512) in the avon longitudinal 
Study of Parents and children, and genetic evidence 
of SHBg and asthma using two-sample Mendelian 
randomisation (Mr), a method of causal inference. 
We meta-analysed two-sample Mr results across two 
large data sets, the trans-national asthma genetics 
consortium genome-wide association study of asthma 
and UK Biobank (over 460 000 individuals combined).
results Observational evidence indicated weak 
evidence of a protective effect of increased circulating 
testosterone on asthma in males in adolescence, but 
no strong pattern of association with SHBg. genetic 
evidence using two-sample Mr indicated a protective 
effect of increased SHBg, with an Or for asthma of 0.86 
(95% ci 0.74 to 1.00) for the inverse-variance weighted 
approach and an Or of 0.83 (95% ci 0.72 to 0.96) 
for the weighted median estimator, per unit increase 
in natural log SHBg. a sex-stratified sensitivity analysis 
suggested the protective effect of SHBg was mostly 
evident in females.
Conclusion We report the first suggestive evidence of a 
protective effect of genetically elevated SHBg on asthma, 
which may provide a biological explanation behind 
the observed asthma sex discordance. Further work is 
required to disentangle the downstream effects of SHBg 
on asthma and the molecular pathways involved.
InTroduCTIon
Observational epidemiological studies suggest that 
males have a higher prevalence of asthma in child-
hood, whereas females have a higher prevalence in 
adolescence and adulthood.1 2 The age at which this 
switch occurs has not been precisely determined, 
with conflicting research on whether puberty is 
associated with the switch in prevalence.1 3 The 
cause of the switch has been suggested to be multi-
factorial4 with sex hormones hypothesised to play a 
role in this switch, due to puberty coinciding with 
fluctuations in levels of circulating sex hormones.5 
The hypothesised involvement of sex hormones 
in asthma is further supported by the acute dete-
rioration of asthma observed during the menstrual 
cycle6 7 (coinciding with heightened sex hormone 
levels), as well as by the known gender dimor-
phism of the immune system8 (with females gener-
ally having stronger innate and adaptive immune 
responses than males in adulthood), and by the vast 
difference in prevalence of autoimmune disorders 
where over 75% of cases are female.9 In animal 
models, testosterone has been indicated to be 
immunosuppressant10 whereas oestrogen is poten-
tially proinflammatory.11
Sex hormone-binding globulin (SHBG) is a 
glycoprotein and the major transporter and puta-
tive regulator of androgens (eg, testosterone) and 
oestrogens. SHBG may also exert direct effects of 
its own independently of the sex hormones it regu-
lates.12 Variation in SHBG levels has been previ-
ously associated with risk of cancer13 and type 2 
diabetes.14 The potential remains that the effects 
of sex hormones may be put to therapeutic use in 
the context of asthma. However, robust evidence of 
their involvement from human population studies 
is first required.
Observational epidemiological studies are often 
subject to confounding and reverse causation. 
Mendelian randomisation (MR) is a method of 
causal inference that uses germline genetic variants 
(usually single nucleotide polymorphisms (SNP)) as 
instrumental variables (IV).15 16 Based on Mendel’s 
Key messages
What is the key question?
 ► Is there evidence for the involvement of sex 
hormones in the development of asthma that 
may explain the sex discordance in asthma 
prevalence?
What is the bottom line?
 ► Increased circulating sex hormone-binding 
globulin appears to be causally associated 
with a decreased risk of asthma, with effects 
stronger in females.
Why read on?
 ► This is the first study to investigate the effects 
of sex hormones on asthma and uses a dual 
observational and genetic epidemiological 
approach drawing on multiple independent 
data sets.
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law of independent assortment, genetic variants are distributed 
independently and randomly with respect to other genetic vari-
ants that are not in linkage disequilibrium and assuming no popu-
lation stratification. Randomisation of genetic variants ensures 
that any association observed between the IVs and the disease 
outcome is most likely explained by an unbiased causal effect of 
the exposure on the outcome, given a set of prior assumptions.16 
This is because MR study design is analogous to a randomised 
controlled trial with genetic variants randomising individuals to 
a higher or lower lifetime exposure to the trait of interest. In 
the case of SHBG as the exposure of interest, carriers of variant 
alleles associated with elevated circulating SHBG in previous 
genome-wide association studies (GWAS) may be considered as 
being genetically randomised to higher lifetime average levels 
of circulating SHBG. MR application is increasingly facilitated 
by the availability of summary statistics from GWAS from large 
consortia, with IV-exposure estimates and IV-outcome esti-
mates derived from different data sets, in an approach termed 
two-sample MR.17
Both SHBG and testosterone levels are highly heritable traits 
with previous GWAS identifying multiple SNPs associated with 
both traits.18 19 The strongest association has been observed 
between the rs12150660 SNP located in the SHBG gene and 
circulating SHBG (p=1.8×10−106), estimated to account 
for ~7.8% of circulating SHBG variation in males and ~3.3% 
in females, in a study with a combined discovery plus replication 
sample size of 28 837 individuals.18 SNPs identified as associated 
with circulating testosterone largely overlap those identified for 
SHBG.
In this study, we test the hypothesis that circulating sex 
hormones have an effect on development of asthma. We 
combine observational evidence using longitudinal sex hormone 
data from a subset of males in the Avon Longitudinal Study of 
Parents and Children (ALSPAC) cohort, with genetic evidence 
from two-sample MR in two large data sets, the Trans-National 
Asthma Genetics Consortium (TAGC) GWAS of asthma and UK 
Biobank.
MeThods
study populations
Avon Longitudinal Study of Parents and Children
The ALSPAC recruited 14 541 pregnant women resident in 
Avon, UK with expected dates of delivery from 1 April 1991 to 
31 December 1992.20 21 A detailed description of the cohort can 
be found in online supplementary methods appendix A1. SHBG 
and total testosterone (TT) were measured in a subset of 513 
males at 9.9, 11.8, 13.8, 15.5 and 17.8 years of age using ELISA 
in peripheral blood samples as previously described.22 Longitu-
dinal sex hormone measurements were not available for females 
in ALSPAC. Bioavailable testosterone (BT) was derived from 
measures of TT and SHBG as previously described.22 Genetic 
data for the ALSPAC children were generated by Sample Logis-
tics and Genotyping Facilities at the Wellcome Trust Sanger 
Institute and LabCorp. Data on asthma in the last 12 months 
were extracted from questionnaires completed by the ALSPAC 
mothers at 10.7, 13.1 and 13.8 years of age, and by the study 
participants themselves at 16.5 and 22.9 years. Details of the 
hormone measurements, genotype preprocessing and derived 
asthma measures can be found in online supplementary methods 
appendix A1.
UK Biobank
The UK Biobank project is a large prospective cohort study of 
approximately 500 000 individuals from across the UK, aged 
40–69 years at recruitment. Details of the study recruitment have 
been previously described.23 24 Genotype imputation and quality 
control (QC) are described in online supplementary methods 
appendix A1. Data on ever having had an asthma diagnosis were 
self-reported by UK Biobank participants by touchscreen ques-
tionnaire. Following genotype-related exclusions and QC, a total 
of 38 337 asthma cases and 296 245 controls remained.
Trans-National Asthma Genetics Consortium genome-wide 
association study
The TAGC performed a large-scale ancestry-specific GWAS 
of asthma25 using a total of 23 948 asthma cases and 118 538 
controls from 66 studies. The subsample of European ancestry 
comprised 19 954 asthma cases and 107 715 controls from 56 
studies, identifying 673 genome-wide significant SNPs. The 
study meta-analysed results from cohorts of individuals with 
both childhood-onset and adult-onset asthma across a range of 
ages. Full summary statistics from the GWAS meta-analysis for 
all analysed SNPs are available online via the GWAS catalogue.26 
The results of the random effects meta-analysis of European 
ancestry were used in all analyses.
statistical analyses
Observational analyses
Cross-sectional associations of sex hormones and asthma at each 
of the five time points in ALSPAC were investigated using serial 
logistic regression in STATA V.14.2. Model 1 was unadjusted 
for the previous measure of asthma/hormone and model 2 was 
adjusted for the previous measure, therefore modelling change 
between time points. Hormone measures were matched with 
their closest asthma response, ensuring asthma (the outcome) 
proceeded the hormone measurement. Analyses were carried out 
in male singletons (n=512). Results of cross-sectional models 
were compared with the path analysis.
In order to test for potential differences in effects between 
time points, path analysis (a type of multiple regression anal-
ysis) was conducted using STATA V.14.2 and STATA structural 
equation model (SEM) builder. Separate generalised SEMs were 
fitted for SHBG, TT and BT and asthma (online supplemen-
tary figures S1–S3 appendix A1). All models were adjusted for 
maternal confounders (maternal smoking, maternal education, 
parity, gestational age, maternal age) as well as participants’ 
exact age. Details of covariate adjustments and the rationale of 
the path analyses can be found in online supplementary methods 
appendix A1.
In order to increase statistical power and counter possible bias 
due to missingness, multiple imputation was used to complete 
missing values in the exposure, outcome and covariates, in both 
the cross-sectional regressions and the path analysis using ICE27 
in STATA V.14.2 (StataCorp, release 14).27 A detailed descrip-
tion of the multiple imputation can be seen in online supple-
mentary appendix A1. Results using the imputed data set were 
compared with the complete case analysis. Descriptions of the 
variables are shown in table 1.
Genetic analyses
Age-dependent effects of SHBG variants
As a preliminary step, we examined whether the effects of 
the SNPs associated with SHBG in the GWAS by Coviello et 
al18 had an age-dependent effect on SHBG and TT using the 
ALSPAC subsample (males aged 9.9–17.8 years). Generalised 
linear regression models were implemented in R V.3.4.1 to 
test cross-sectional associations between each of the SNPs and 
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either z-scored SHBG, TT or BT at each of the five time points, 
adjusting for the top 20 derived principal components (PC).
Mendelian randomisation
Two-sample MR was used to investigate the hypothesised causal 
effect of SHBG on asthma. The two-sample approach requires 
only summary-level data from GWAS, enabling SNP-outcome 
and SNP-exposure effects to be derived from different data sets. 
The assumptions of two-sample MR are similar to those of 
one-sample MR, while additionally requiring that the summary 
statistics for both the exposure and the outcome are derived from 
studies of comparable populations. Analyses were performed 
using the TwoSampleMR R package, part of MR-Base.17 The 
inverse-variance weighted (IVW) approach was used as a primary 
analysis, with two complementary estimation methods as sensi-
tivity analyses to assess horizontal pleiotropy (where the genetic 
variant associates with the outcome via an independent pathway 
to the exposure): a weighted-median estimator28 and MR Egger 
regression.29 Evidence for effect size dilution was assessed using 
the unweighted I2 statistic,30 also called the I2GX statistic.
SNP-asthma effects
Individual-level data from UK Biobank and summary statistics 
from the TAGC GWAS of asthma (where ALSPAC was a contrib-
uting cohort) were used to derive SNP-asthma effects. In UK 
Biobank logistic regressions in R 3.4.1 were used to determine 
the effects of each SNP on self-reported ever asthma, adjusted 
for genotype array (chip), sex and top 40 PCs. For TAGC, the 
results of the random effects meta-analysis of European ancestry 
were used.
IV combinations
Two combinations of independent SHBG IVs were used, based 
on associations reported in the previous GWAS (online supple-
mentary table S5)18. IV combination A comprised entirely SNPs 
located in the SHBG gene, determined as independent variants in 
the conditional analysis by Coviello et al.18 Variants in the SHBG 
gene region are less likely to be subject to horizontal pleiotropy. 
This resulted in three variants comprising IV combination A. For 
IV combination B, all SNPs identified in the previous GWAS of 
SHBG were used (nine variants), including those in combina-
tion A. We excluded only SNPs located on the X-chromosome 
(rs1573036), SNPs with a minor allele frequency <0.01 in UK 
Biobank (rs6258), or SNPs unavailable in the Haplotype Refer-
ence Consortium-imputed UK Biobank data set (rs2411984). 
This approach using two complementary IV combinations has 
been used previously for assessing the effects of SHBG on metab-
olites31 in an MR framework. The diagram in figure 1 presents 
an overview of the analyses performed.
Meta-analysis
Final MR estimated effects of SHBG on asthma resulting from 
both the TAGC GWAS and UK Biobank were combined in a 
fixed effects meta-analysis using the metafor R package. The 
combined meta-analysis sample size consisted of 462 251 indi-
viduals of which 58 291 were asthma cases.
Sex-stratified analysis
Since we hypothesised that the effects of SHBG were likely to 
be sex specific, MR analyses were repeated on a sex-stratified 
sample in UK Biobank, separately for male (n=154 564 of which 
16 308 asthma cases) and female participants (n=180 018 of 
which 22 029 asthma cases).
resulTs
observational analyses
Descriptions of the different sex hormone measurements, 
asthma reports and confounder variables included in the obser-
vational analyses, with percentage missingness for each variable, 
are presented in table 1.
Serial cross-sectional models of SHBG, TT and BT in males 
revealed little evidence of an association between SHBG and 
asthma (model 1 in online supplementary table S1 appendix 
A1), but a consistent inverse association between TT and BT 
Table 1 Descriptions of the different sex hormone, asthma and 
confounder variables included in the observational analyses, with 
percentage missingness in the original variables out of a total 
subsample size of 512 males in the ALSPAC cohort
Age at measurement n Mean (sd)
Missing 
(%)*
Imputation 
method 
SHBG
  9.9 441 92.33 (43.67) 13.9 PMM
  11.8 482 74.96 (37.47) 5.9 PMM
  13.8 416 45.41 (26.03) 18.8 PMM
  15.5 463 30.82 (13.33) 9.6 PMM
  17.8 427 26.26 (12.39) 16.6 PMM
Total testosterone
  9.9 440 0.82 (0.09) 14.1 PMM
  11.8 481 1.54 (1.23) 6.1 PMM
  13.8 414 9.05 (4.66) 19.1 PMM
  15.5 463 14.8 (2.72) 9.6 PMM
  17.8 412 16.48 (2.62) 19.5 PMM
Bioavailable testosterone
  9.9 441 0.17 (0.07) 14.1 PMM
  11.8 482 0.42 (0.47) 6.1 PMM
  13.8 414 3.84 (2.57) 19.1 PMM
  15.5 464 7.33 (1.97) 9.6 PMM
  17.8 413 9.01 (1.97) 19.5 PMM
Asthma
  10.7 467 – 8.8 Logit
  13.1 476 – 7.0 Logit
  13.8 455 – 11.1 Logit
  16.5 473 – 7.6 Logit
  22.9 250 – 51.2 Logit
Maternal confounders
  Maternal education 477 – 6.8 Mlogit
  Maternal smoking 481 – 6.1 Mlogit
  Parity 474 – 7.4 Logit
  Maternal age 492 363.52 (52.52) 3.9 Regress
  Gestational age 488 39.42 (1.86) 4.7 Regress
*As a percentage of total size of male subsample that had at least two hormone 
measures at two time points (n=512). Missingness estimate does not take into 
account non-overlap between asthma responses and hormone measurements. For 
example, although there are n=440 with testosterone at 9.9 years and n=467 with 
asthma data at 10.7, individuals with data do not fully overlap.
ALSPAC, Avon Longitudinal Study of Parents and Children; Logit, 
logistic regression; Mlogit, multinomial logistic regression; PMM, predictive mean 
matching; Regress, linear regression; SHBG, sex hormone-binding globulin. 
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on asthma after 11.8 years (model 1 in online supplementary 
tables S2 and S3 appendix A1). However, CIs were wide for 
both TT and BT and overlapped the null. Serial cross-sectional 
models using multiple imputation and adjusted for previous 
measures of asthma and either SHBG, TT or BT (table 2) 
demonstrated similar estimates to the base models. For SHBG 
there was an OR for asthma of 0.96 (95% CI 0.74 to 1.24), 
1.54 (95% CI 0.71 to 3.37), 1.32 (95% CI 0.64 to 2.70), 1.18 
(95% CI 0.67 to 2.06) and 1.02 (95% CI 0.57 to 1.83) at 9.9, 
11.8, 13.8, 15.5 and 17.8 years, respectively. For TT there was 
an OR for asthma of 1.12 (95% CI 0.87 to 1.43), 0.85 (95% 
CI 0.55 to 1.32), 0.80 (95% CI 0.46 to 1.38), 0.89 (95% CI 
0.59 to 1.35) and 0.71 (95% CI 0.43 to 1.16) at the respec-
tive time points, whereas for BT there was an OR of 1.02 (95% 
CI 0.77 to 1.34), 0.79 (95% CI 0.47 to 1.34), 0.86 (95% CI 
0.48 to 1.55), 0.87 (95% CI 0.56 to 1.35) and 0.87 (95% CI 
0.54 to 1.41) at the respective time points. Comparison of the 
different cross-sectional models can be seen in online supple-
mentary tables S1–S3 appendix A1.
Results of path analyses using multiple imputation (online 
supplementary table S4 and figures S1–S3 appendix A1) were 
similar to results from the serial cross-sectional models, with no 
clear evidence of an association between SHBG and asthma and 
only weak evidence for a protective effect of increased TT on 
asthma in adolescence (table 2). Since there was little evidence 
of an association at the individual time points in either the serial 
cross-sectional or the path analysis we did no test for differences 
between time points in the path analysis. We therefore present 
the results of the simpler cross-sectional models in table 2, with 
the results of the path analysis in online supplementary table S4 
appendix A1.
Genetic analyses
Age-dependent effects of SHBG variants
Serial cross-sectional analysis of the effect of the SHBG SNPs in 
ALSPAC revealed that only the rs12150660 variant had a consis-
tent effect on SHBG levels and an age-dependent effect on TT 
and BT (figure 2 and online supplementary appendix A2). For 
SHBG there was an estimated 0.41 (95% CI 0.24 to 0.59), 0.39 
(95% CI 0.23 to 0.55), 0.24 (95% CI 0.06 to 0.42), 0.38 (95% 
CI 0.21 to 0.55) and 0.38 (95% CI 0.20 to 0.55) SD increase in 
circulating SHBG (nmol/L) per copy of the rs12150660 variant 
allele (GT or TT genotype) at the ages of 9.9, 11.8, 13.8, 15.5 
and 17.8 years, respectively. For TT, there was no evidence of an 
association at the earlier ages, however an effect was observed 
at the later time points. There was an estimated −0.03 (95% 
CI −0.21 to 0.15), −0.07 (95% CI −0.24 to 0.10), 0.27 (95% 
CI 0.09 to 0.45), 0.30 (95% CI 0.13 to 0.47) and 0.30 (95% 
CI 0.13 to 0.48) SD increase in testosterone per copy of the 
Figure 1 Flow diagram of the Mendelian randomisation (MR) analyses performed. GWAS, genome-wide association studies; SHBG, sex hormone-
binding globulin; SNP, single nucleotide polymorphism; TAGC, Trans-National Asthma Genetic Consortium.  
Table 2 Results of serial cross-sectional analysis of SHBG, TT or BT on asthma (using multiple imputation) adjusted for previous measures of 
asthma and sex hormones (where available) at five time points in a subsample of 512 males in ALSPAC
Age at sex 
hormone 
exposure 
(years)
Age at asthma 
outcome 
(years) or* (95% CI) shbG
n with data 
for shbG (% 
missing)†
or* (95% CI) total 
testosterone
n with data for 
total testosterone 
(% missing)†
or* (95% CI) 
bioavailable 
testosterone
n with data for 
bioavailable 
testosterone (% 
missing)
n after 
multiple 
imputation
9.9 10.7 0.96 (0.74 to 1.24) 381 (26) 1.12 (0.87 to 1.43) 381 (26) 1.02 (0.77 to 1.34) 381 (26) 512
11.8 13.1 1.54 (0.71 to 3.37) 339 (34) 0.85 (0.55 to 1.32) 338 (34) 0.79 (0.47 to 1.34) 338 (34) 512
13.8 13.8 1.32 (0.64 to 2.70) 318 (38) 0.80 (0.46 to 1.38) 315 (38) 0.86 (0.48 to 1.55) 315 (38) 512
15.5 16.5 1.18 (0.67 to 2.06) 263 (49) 0.89 (0.59 to 1.35) 262 (49) 0.87 (0.56 to 1.35) 262 (49) 512
17.8 22.9 1.02 (0.57 to 1.83) 144 (72) 0.71 (0.43 to 1.16) 99 (81) 0.87 (0.54 to 1.41) 99 (81) 512
*OR for asthma per SD increase in either SHBG, TT or BT.
†n refers to the number of individuals with complete data in the analysis of specified hormone (before multiple imputation). Per cent missing refers to the fraction of individuals missing some 
data (either asthma measurements, hormone measurements or covariates, where covariates include any previous measurement of asthma and hormone) at each time point, which were 
subject to multiple imputation.
ALSPAC, Avon Longitudinal Study of Parents and Children; BT, bioavailable testosterone; SHBG, sex hormone-binding globulin; TT, total testosterone. 
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rs12150660 variant allele at the ages of 9.9, 11.8, 13.8, 15.5 
and 17.8 years, respectively. For BT, there was an inverse pattern 
of association to that of SHBG, consistent with its derivation 
from the assayed SHBG and TT measures. There was a −0.37 
(95% CI −0.54 to −0.19), −0.15 (95% CI −0.32 to 0.02), 
0.10 (95% CI −0.09 to 0.28), −0.10 (95% CI −0.27 to 0.07) 
and −0.23 (95% CI −0.40 to −0.05) SD change in BT per 
copy of the rs12150660 variant allele at the five respective 
time points. There was also some evidence for an effect of 
rs1641537 and rs8023580 on SHBG and BT levels in childhood 
(figure 2 and online supplementary appendix A2). However, 
the remaining SNPs indicated inconsistent patterns of effect on 
SHBG, TT and BT across the five time points.
Mendelian randomisation
In contrast to the observational findings, there was evidence of 
a protective effect of increased SHBG on asthma when using 
MR (figure 3 and online supplementary tables S6-S7 and supple-
mentary table S8 appendix A1). In IVW analyses, there was an 
estimated 0.86 (95% CI 0.74 to 1.00) OR per unit increase in 
log SHBG for IV combination A and 0.94 (95% CI 0.82 to 1.09) 
OR for asthma when using IV combination B. Meta-analysed 
weighted-median estimates were similar, with a 0.83 (95% CI 
0.72 to 0.96) OR for asthma per unit increase in log SHBG for IV 
combination A and an estimated 0.85 (95% CI 0.74 to 0.97) OR 
for asthma for IV combination B. Wider CIs and smaller effect 
sizes in the IVW estimated effects of combination B may indicate 
the presence of directional pleiotropy, which the IVW method 
is not robust to. This conclusion is supported by the results of 
the more conservative combination A, which is less likely to 
introduce pleiotropic effects. Estimates from MR Egger regres-
sion for combination B (MR Egger regression was not applied 
to combination A as there were not enough SNPs) were in the 
same direction as estimates from the other two methods with 
a 0.81 (95% CI 0.60 to 1.09) OR for asthma per unit increase 
in log SHBG, but with wider CIs that spanned the null (online 
supplementary figure S4 appendix A1), possibly reflecting the 
lower statistical power of MR Egger regression. There was no 
indication of dilution in the MR Egger regression estimates (I2 
for dilution=0.99). Heterogeneity tests for combination B in 
UK Biobank indicated some evidence for heterogeneity between 
SNPs for the IVW method (Cochran’s Q=15.4, Q p=0.051), 
with an I2 for heterogeneity between SNPs of 48.1%. There was 
weak evidence for directional pleiotropy in combination B in 
Figure 2 Serial cross-sectional associations of estimated SD change in SHBG, bioavailable testosterone (BT) or total testosterone (TT), per copy of 
SHBG-raising allele for nine genetic variants used as SHBG instrumental variables (IV) in the Mendelian randomisation (MR) analyses. Associations 
assessed in a subset of Avon Longitudinal Study of Parents and Children (ALSPAC) males across five available time points. SHBG, sex hormone-binding 
globulin. 
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UK Biobank, estimated using the MR Egger intercept (Egger 
intercept=1.01, p=0.173). Scatterplots of the SNP-asthma and 
SNP-SHBG effects can be seen in online supplementary figures 
S5 and S6 appendix A1.
Sex-stratified MR analysis
The sex-stratified analysis in UK Biobank indicated differences 
in MR estimated effects between females and males (figure 4 and 
figure 5). For females, there was an IVW estimated 0.80 (95% 
CI 0.63 to 1.01) OR for asthma per unit increase in log SHBG 
when using IV combination A, whereas in males there was an 
IVW estimated 0.95 (95% CI 0.77 to 1.18) OR for asthma. For 
the weighted-median estimated effect there was an OR of 0.80 
(95% CI 0.64 to 0.98) for females and an OR of 0.93 (95% 
CI 0.73 to 1.17) for males. When using IV combination B, 
similar evidence for a protective effect of SHBG on asthma was 
obtained in females, whereas these estimates largely agreed with 
estimates based on IV combination A in males. Larger effects 
were observed in females when using the weighted-median esti-
mator and MR Egger regression sensitivity analyses than the 
IVW estimate, indicating horizontal pleiotropy in IV combina-
tion B (complete description of results in online supplementary 
tables S9-S10 and supplementary result appendix A1).
dIsCussIon
We have conducted a novel hybrid investigation of the associa-
tions of SHBG and testosterone with asthma using dual longitu-
dinal data analysis and an MR design. Observational evidence 
indicated some evidence of a protective effect of increased TT 
on asthma, but no clear pattern for SHBG. Genetic evidence 
using two-sample MR indicated a protective effect of increased 
SHBG on asthma, with the effects most evident among females 
and indications of horizontal pleiotropy in the more liberal 
combination of IVs.
Figure 3 Meta-analysis forest plots of the estimated effects of the two SHBG instrumental variable (IV) combinations on asthma, in the TAGC 
genome-wide association studies (GWAS) and UK Biobank. Fixed effects  (FE)  meta-analysis of (A) the IVW estimated effect of IV combination A on 
asthma, (B) the IVW estimated effect of IV combination B on asthma, (C) the weighted-median (WM) estimated effect of IV combination A on asthma, 
(D) the WM estimated effect of IV combination B on asthma. IVW, inverse-variance weighted; SHBG, sex hormone-binding globulin; TAGC, Trans-
National Asthma Genetic Consortium. 
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Figure 4 Forest plots of the individual instrumental variable (IV) effects in the female subsample of UK Biobank using the two combinations of 
IVs to assess the genetic effect of sex hormone-binding globulin (SHBG) on asthma. MR effect sizes are presented as log odds for asthma per unit 
increase in log SHBG. Methods used include the weighted-median (All-WM), MR Egger regression (All-MR Egger) and inverse-variance weighted (All-
IVW). (A) IV combination A includes nine single nucleotide polymorphisms (SNP) and (B) IV combination B includes three SNPs located in the SHBG 
gene. MR, Mendelian randomisation. 
Figure 5 Forest plots of the individual instrumental variable (IV) effects in the male subsample of UK Biobank using the two combinations of IVs to 
assess the genetic effect of sex hormone-binding globulin (SHBG) on asthma. Mendelian randomisation (MR) effect sizes are presented as log odds 
for asthma per unit increase in log SHBG. Methods used include the weighted-median (All-WM), MR Egger regression (All-MR Egger) and inverse-
variance weighted (All-IVW). (A) IV combination A includes nine single nucleotide polymorphisms (SNP) and (B) IV combination B includes three SNPs 
located in the SHBG gene.
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Notably, the sole genetic variant to demonstrate a consistent 
effect on circulating SHBG in ALSPAC was the rs12150660 SNP. 
However, there was no discernible effect of the variant on TT 
levels until puberty, gradually increasing during teenage years. 
This observation fits with previously reported biological under-
standing of the polymorphism, suggesting that its location near a 
pentanucleotide repeat which affects SHBG expression levels in 
vitro32 drives the association. The remaining eight SNPs showed 
inconsistent patterns of association with circulating SHBG. 
However, associations may not have replicated because of lack 
of statistical power due to the small sample size or because 
effects of these SNPs may not be evident until later life (the orig-
inal GWAS included only adult participants).
Although previous hypotheses have suggested an immu-
nological/inflammatory effect of SHBG on asthma, MR does 
not distinguish between which mechanistic pathways link the 
exposure to the outcome. Therefore, any indication of SHBG’s 
causality does not imply a biological or immunological effect of 
sex hormones.
The differences in effects of SHBG on asthma between sexes 
observed have the potential to explain the increase in female asth-
matics observed after puberty. Since the evidence indicates that an 
increase in SHBG is protective against asthma, then the decrease in 
circulating SHBG observed in females during puberty33 34 may be a 
biological trigger for development of asthma.
Little previous evidence exists of the effects of sex hormones 
on asthma. We have not been able to find any previous literature 
that has investigated the effect of circulating SHBG on asthma 
that could be used to facilitate comparisons with our MR esti-
mated effects.
strengths and limitations
The current study has several major strengths. It is based on 
strong biological rationale with a hypothesis that has been exten-
sively reviewed.35 The biological hypothesis is underpinned by 
an established observation of sex discordance in asthma preva-
lence, previously corroborated in ALSPAC.36 The current anal-
yses combine observational evidence with genetic evidence from 
MR, using a triangulation approach,37 and multiple complemen-
tary approaches and data sets, strengthening the conclusions.
Observational analyses
In the observational analysis of the ALSPAC subsample, testos-
terone distribution at 13.8 years was severely non-normal which 
may lead to imprecision of the SEs of the estimated effects. It was 
hypothesised that this was due to some but not all males having 
transitioned through puberty. However, since the non-normality 
is observed only at the one time point, estimates from this single 
measure do not alter the conclusions.
All male hormone measurements were carried out using 
immunoassays, with evidence suggesting that immunoassays 
lack precision, particularly in children, where testosterone levels 
are low.38 At the earliest time point, a large number of measure-
ments had to be set to the lowest detectable assay value. Sample 
sizes were also small due to the non-overlap of individuals with 
reports of asthma and those with measured sex hormones, with 
a large fraction of missing measurements, particularly at the final 
time point (table 1). We used multiple imputation to attempt to 
increase power for the analysis and additionally included reports 
of wheezing in the last 12 months as auxiliary variables that may 
predict asthma in order to aid the multiple imputation. Assuming 
an adequate number of imputations and valid imputation, that is, 
all data are missing at random and the imputation and analysis 
models are correct, the results from multiple imputation should 
be unbiased. However, multiple imputation will lead to large SEs 
and wide CIs if there is little overall information in the data sets. 
After multiple imputation, we observed large SEs and wide CIs in 
our estimated effects, indicating that statistical power to detect 
an association may have remained low in the sample size of 512 
individuals despite imputation. All observational analyses were 
conducted in a subsample of males, and the observational effects 
of SHBG and testosterone on asthma in females have not been 
assessed, with the effects likely to differ substantially from males 
given the differences in effects between the two sexes observed 
in the genetic analyses.
Genetic analyses
A major limitation of the genetic analyses is that a two-sample 
MR-based approach estimates average lifetime effects of an 
exposure on a disease outcome and does not distinguish between 
changes in the magnitude of that effect during different critical 
periods of the life course. This means that overall effect esti-
mates may not be representative of true effects at all ages if the 
exposure only affects the outcome at certain critical periods 
of the life course. This is particularly true for diseases such as 
asthma which are known to wax and wane. It was therefore 
not possible to determine if SHBG is causal to the ‘adolescent 
switch’ observed in asthma prevalence or if the decreased risk 
is an unrelated early-life or later-life effect of SHBG on asthma. 
Future studies could attempt to develop methods to investigate 
time-varying exposures (eg, SHBG) on time-varying outcomes 
(eg, asthma) in an MR framework.
We did not attempt to stratify the MR analysis by age of 
asthma onset due to measurement error being a potential major 
problem in the UK Biobank, as the adult participants aged 40–69 
at recruitment were asked to recall age of asthma onset, likely 
leading to substantial imprecision in reports. Additionally, as 
SNPs used as SHBG IVs in the MR were derived from adult 
population GWAS, we considered them unlikely to proxy SHBG 
levels as robustly in childhood, given the results of the SNP vali-
dation step in the ALSPAC subsample (shown in figure 2), which 
would further reduce statistical power to detect an association. 
Similarly, although the TAGC GWAS consortium performed a 
sensitivity analysis where participants were stratified into child-
hood-onset asthma and adult-onset asthma, the cut-off age for 
childhood-onset asthma was 16 years of age, by which time any 
changes linked to sex hormones will have already occurred. 
Therefore, we did not conduct an age-of-onset stratified MR 
to compare the effects of sex hormones prepuberty versus post-
puberty. In the sex-stratified analysis in UK Biobank, the lower 
number of asthma cases in the male subsample compared with 
the female subsample may have led to lower statistical power 
and wider CIs, which may explain the differences in results. 
Given that the CIs overlap substantially, we cannot determine 
with certainty whether effects are specific to females.
The genetic correlation between SHBG and testosterone (as 
well as other hormones such as oestrogens) presents a problem 
in MR and it was not possible to identify SNPs associated with 
testosterone that were not also associated with SHBG. A previous 
GWAS of testosterone19 identified several polymorphisms asso-
ciated with testosterone, including the rs12150660 variant; 
however, all reported variants were also identified as associated 
with SHBG. It may be possible to investigate such situations in the 
future using multivariate MR.39 Winner’s curse is a likely issue in 
two-sample MR studies that derive SNP-exposure estimates from 
the same GWAS used to select IVs, and although we used effect 
estimates from the combined discovery and replication samples of 
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the published GWAS of SHBG, which may mitigate effects due to 
winner’s curse, some residual bias may remain.
Overall, we have performed multiple analyses at several 
different time points in order to disentangle the complex relation-
ship between the various sex hormones and asthma. The possibility 
of spurious results arising due to chance cannot therefore be ruled 
out. Future work should attempt to replicate these findings in inde-
pendent data sets in order to confirm the current conclusions.
ConClusIon
In this study, we present the first tentative evidence that increased 
circulating SHBG is causally associated with a decreased risk of 
asthma, with effects stronger in females. Although findings from 
the observational epidemiological analysis indicated little evidence 
of an effect of SHBG on asthma and only weak evidence for a 
protective effect of increased testosterone on asthma in the subsa-
mple of males, genetic epidemiological approach indicated some 
evidence of a protective effect of increased SHBG on asthma. 
These findings from multiple independent data sets align with 
previous hypotheses suggesting that fluctuating sex hormones, 
particularly during puberty, may promote asthma development in 
females. These suggestive associations may provide some insight 
into the biological mechanisms behind the observed asthma sex 
discordance as well as the overall pathology of asthma. Whether 
the effects of sex hormones are meaningful as potential interven-
tion targets is unknown and further work is required to disentangle 
the downstream effects of SHBG on asthma.
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